Title
Orexins and fear: Implications for the treatment of anxiety disorders
Date Issued
01 September 2015
Access level
open access
Resource Type
review
Author(s)
Universitat Pompeu Fabra
Publisher(s)
Elsevier Ltd
Abstract
An understanding of the neurobiological mechanisms involved in the regulation of fear is essential for the development of new treatments for anxiety disorders, such as phobias, panic, and post-traumatic stress disorders (PTSD). Orexins, also known as hypocretins, are neuropeptides located exclusively in hypothalamic neurons that have extensive projections throughout the central nervous system. Although this system was initially believed to be primarily involved in the regulation of feeding behavior, recent studies have shown that orexins also modulate neural circuits implicated in the expression and extinction of fear memories. Here, we discuss recent findings involving orexins in anxiety disorders and current clinical trials using orexin ligands that could be applied to identify new therapies for diseases characterized by pathological fear.
Start page
550
End page
559
Volume
38
Issue
9
Language
English
OCDE Knowledge area
Neurociencias
Subjects
Scopus EID
2-s2.0-84940787032
PubMed ID
Source
Trends in Neurosciences
Resource of which it is part
Trends in Neurosciences
ISSN of the container
01662236
Source funding
Generalitat de Catalunya
Sponsor(s)
This work was supported by the Instituto de Salud Carlos III grants, #PI13/00042 and #RD12/0028/0023 (RTA-RETICS), by the Spanish Ministry of Science #SAF2011-29864 and #SAF2014-59648-P, National Plan on Drugs #2014I019, and the Catalan Government (SGR2014-1547). Important contributions from several authors could not be included due to space limitations. We thank Miquel Angel Serra for invaluable assistance in the documentation of the clinical trials with orexin antagonists.
Sources of information:
Directorio de Producción Científica
Scopus